Helsinn, a privately-owned pharmaceutical group with a portfolio of marketed cancer care products, a strong development pipeline and 700 employees globally, is committed to improving the quality of life of patients through the development of high-quality cancer-care therapies and supportive care. Through its unique B-to-B and B-to-C business model, Helsinn’s products are distributed in approximately 190 countries, with a direct presence in US and China, thanks to their expertise in R&D, manufacturing, licensing and commercialization.